Abstract:Background and Aim: Esomeprazole is the S‐isomer of omeprazole, with a stronger acid suppressive effect than omeprazole. This open, randomized crossover study was designed to evaluate the effect of esomeprazole and another proton‐pump inhibitor, rabeprazole, on intragastric pH in healthy Chinese. Methods: Thirty‐six healthy volunteers (26 men and 10 women, aged between 20 and 31 years) were enrolled. Subjects were given either esomeprazole 40 mg ( n = 18) or rabeprazole 10 mg ( n = 18) orally once daily for 5 days during the first dosing period, then the other medicine at the set dosage for the second dosing period. The two periods were separated by a 14‐day washout phase. The doses were chosen according to the State Food and Drug Administration of China for the treatment of acid‐related diseases. Intragastric pH was continuously monitored for 24 h on days 1 and 5 of each dosing period. CYP2C19 genotypes were analyzed to identify the extensive metabolizers (EM) and poor metabolizers (PM). Results: The percentage of time with intragastric pH >4 was significantly higher ( P < 0.001) in subjects receiving esomeprazole than in those receiving rabeprazole in the first 4 h after administration of the first dose (70.65% vs 44.87%), at 24 h on day 1 (73.7% vs 54.8%) and at 24 h on day 5 (84.2% vs 76.2%). The median intragastric pH was also higher in subjects receiving esomeprazole than in those receiving rabeprazole in the first 6 h, day 1 and day 5 ( P ≤ 0.001). The percentage of subjects with intragastric pH >4 for at least 16 h on day 1 (63.9% vs 33.3%) and on day 5 (88.9% vs 61.1%) was higher after administration of esomeprazole than after rabeprazole (both P < 0.05). On genotype analysis, 28 of the subjects were EM and eight were PM. Those who were PM tended to have a higher, albeit not statistically significant, percentage of time with intragastric pH >4 and the median 24‐h intragastric pH than those who were EM. Both drugs were well tolerated. Conclusions: Esomeprazole 40 mg orally once daily is more effective and faster in increasing intragastric pH than rabeprazole 10 mg orally once daily, and thus offers a potential for improved efficacy in acid‐related diseases.

The Effect of Esomeprazole on Reflux Esophagitis

Clinical efficacy of omeprazole combined mosapride in treating reflux esophagitis

<TITLE>COMPARATIVE EFFECTS OF ESOMEPRAZOLE AND OMEPRAZOLE IN TREATING REFLUX ESOPHAGITIS OF THE AGED

Clinicai Investigation on Esomeprazoie Treatment of Sixty-Nine Asthmatic Patients with Gastroesophageal Reflux Symptoms

Effect of Esomeprazole and Rabeprazole on Intragastric Ph in Healthy Chinese: an Open, Randomized Crossover Trial

Clinical Effect of Esomeprazole Combined with Trimebutine Maleate Tablets for Treatment of Erosive Esophagitis

Clinical comparison of rabeprazole and omeprazole in the treatment of reflux esophagitis

The Benefits Of Combination Therapy With Esomeprazole And Rebamipide In Symptom Improvement In Reflux Esophagitis: An International Multicenter Study

Quality of Life and Cost-Effectiveness of Combined Therapy for Reflux Esophagitis.

Clinical observation and esophageal dynamical analysis of esomeprazole combined with itopride in the treatment of gastroesophageal relfux disease

Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis

The Efficacy of Esomeprazole in Preventing Stress Ulcer in the Mechanical Ventilation Patients

Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole

Effect of Helicobacter pylori eradication on reflux esophagitis therapy: a multi-center randomized control study.

Analysis of the Effect of Omeprazole and Tegaserod on Non-Erosive Reflux Disease

Clinical Investigation of Paryngolaryngitis As Extra-Esophageal Symptoms of Gastroesophageal Reflux Disease

The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis

Behavior Intervention Therapy in Patients with Gastroesophageal Reflux Disease

Comparison on relief of symptoms and acid suppression of Rabeprazole and Omeprazole on reflux esophagitis in aged

Effect of intravenous esomeprazole on gastric acid secretion in rats

Effects of 6-12 months of esomeprazole treatment on the gastric mucosa